高剂量与佐剂三价流感疫苗比较效果:回顾性队列研究
本研究利用美国Optum数据库的理赔数据,回顾性比较2016/17和2017/18两个以A/H3N2为主的流感季中,65岁及以上老年人接种三价高剂量流感疫苗(HD-IIV3)与佐剂三价流感疫苗(aIIV3)后呼吸道相关住院率。合并两个季节,HD-IIV3相对aIIV3的呼吸道住院相对疫苗效果(rVE)为12%(95%CI 3.3%-20%)。
要点
- 合并两个流感季,HD-IIV3较aIIV3呼吸道住院rVE为12%(95%CI 3.3%-20%)。
- 2016/17季rVE为13%(95%CI -6.4%至32%),2017/18季为12%(95%CI 2.1%-21%)。
- 研究为回顾性队列,使用理赔数据并调整人口学、合并症、既往接种和地理因素。
核心结论
- 在兩個以A/H3N2为主的流感季合并分析中,美国大型全国性管理式医疗公司老年会员接种HD-IIV3与较aIIV3更少的呼吸道住院相关。
研究设计与样本
- 回顾性队列研究,使用Optum Clinformatics® Data Mart理赔数据,比较2016/17和2017/18流感季65岁及以上老年人接种HD-IIV3与aIIV3的结局率。
- 采用既往事件率比(PERR)方法处理时间固定未测量混杂偏倚。
主要发现
- 2016/17季识别HD-IIV3接种者842,282例、aIIV3接种者34,157例;2017/18季识别HD-IIV3接种者1,058,638例、aIIV3接种者189,636例。
- 合并两个季节,HD-IIV3相对aIIV3的呼吸道相关住院rVE为12%(95%CI 3.3%-20%)。
- 2016/17季rVE为13%(95%CI -6.4%至32%);2017/18季rVE为12%(95%CI 2.1%-21%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adults 65 years and older (seniors) experience more complications following influenza infection than younger adults. We estimated the relative vaccine effectiveness (rVE) of a trivalent high dose (HD-IIV3) versus an adjuvanted trivalent influenza vaccine (aIIV3) in seniors for respiratory-related hospitalizations. METHODS: We conducted a retrospective cohort study using claims data from Optum's Clinformatics® Data Mart to compare outcome rates between seniors who received HD-IIV3 versus aIIV3 during the 2016/17 and 2017/18, predominantly A/H3N2 respiratory seasons. Rates were adjusted for demographic characteristics, comorbid conditions, previous influenza vaccination, and geography. We used the previous event rate ratio (PERR) approach to address bias by time-fixed unmeasured confounders. RESULTS: We identified 842,282 HD-IIV3 and 34,157 aIIV3 recipients for the 2016/17 season and 1,058,638 HD-IIV3 and 189,636 aIIV3 recipients for the 2017/18 season. The pooled rVE of HD-IIV3 versus aIIV3 for respiratory-related hospitalizations over both seasons was 12% (95% confidence interval: 3.3%-20%); 13% (-6.4% to 32%) for the 2016/17 season and 12% (2.1%-21%) for the 2017/18 season. CONCLUSIONS: Pooled over two predominantly A/H3N2 respiratory seasons, HD-IIV3 was associated with fewer respiratory hospital admissions than aIIV3 in senior members of large national managed health care company in the U.S.
引用
- van Aalst R, Gravenstein S, Mor V, et al. Comparative effectiveness of high dose versus adjuvanted influenza vaccine: A retrospective cohort study. Vaccine. 2019. PMID: 31606249. doi:10.1016/j.vaccine.2019.09.105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。